OSE — Ose Immunotherapeutics SA Share News
0.000.00%
Last trade - 00:00- €44.94m
- €57.66m
- €2.69m
Brief: OSE Immunotherapeutics Presents Preclinical Data On Lymphoblastic Leukemia Treatment OSE-127
OSE Immunotherapeutics rallies on positive data for COVID-19 vaccine candidate
Brief: OSE Immunotherapeutics Announces Positive Analysis Of First Data Of CoVepiT
Brief: Ose Immunotherapeutics Says First Patient Randomized In Phase 2 Trial Evaluating Tedopi® With Opdivo®
Study results for cancer treatment boost OSE Immunotherapeutics shares
Brief: Ose Immunotherapeutics Presented First Positive Results Data On ON CLEC-1
Brief: OSE Immunotherapeutics To Present New Preclinical Data At Bispecific Antibody And Immunology Conferences
Brief: OSE Immunotherapeutics Receives New European Patent Notice Of Allowance For Tedopi®
Brief: Boehringer Ingelheim, Ose Immunotherapeutics: First Patient Dosed In Phase 1 Trial Evaluating BI 765063 Combined with Ezabenlimab
Brief: Boehringer Ingelheim, Ose Immunotherapeutics Present Phase 1 Results With Sirpα Inhibitor Bi 765063 In Advanced Solid Tumors At ESMO
Brief: Ose Immunotherapeutics, Boehringer Ingelheim To Present Phase 1 Results With Inhibitor BI 765063
Brief: OSE Immunotherapeutics's Tedopi® Receives U.S Patent Notice Of Allowance
Brief: OSE Immunotherapeutics: First Patient Randomized In Phase 2 Clinical Trial Of Tedopi
Brief: Ose Immunotherapeutics And ARCAGY-GINECO Announce First Patient Randomized In Phase 2 Clinical Trial Evaluating Tedopi® In Combination With Pembrolizumab In Ovarian Cancer
Brief: Servier And Ose Immunotherapeutics Announce Enrollment Of First Patient In Ose-127/S95011 Phase 2 Clinical Trial In Sjögren’S Syndrome
Brief: OSE Immunotherapeutics Announces Voluntary Pause Of Enrollment In CoVepiT Phase 1 Study
Brief: OSE Immunotherapeutics Receives Eur 10 Mln Payment From EIB
Brief: Ose Immunotherapeutics Announces Manufacturing Agreement With Cenexi
Brief: OSE Immunotherapeutics Launches Phase 2 Trial Of Tedopi With Opdivo In Lung Cancer